JP2024156682A5 - - Google Patents

Download PDF

Info

Publication number
JP2024156682A5
JP2024156682A5 JP2024110688A JP2024110688A JP2024156682A5 JP 2024156682 A5 JP2024156682 A5 JP 2024156682A5 JP 2024110688 A JP2024110688 A JP 2024110688A JP 2024110688 A JP2024110688 A JP 2024110688A JP 2024156682 A5 JP2024156682 A5 JP 2024156682A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
seq
cell receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024110688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024156682A (ja
Filing date
Publication date
Priority claimed from JP2020065482A external-priority patent/JP2020117519A/ja
Application filed filed Critical
Publication of JP2024156682A publication Critical patent/JP2024156682A/ja
Publication of JP2024156682A5 publication Critical patent/JP2024156682A5/ja
Pending legal-status Critical Current

Links

JP2024110688A 2012-05-16 2024-07-10 癌幹細胞を標的とした癌ワクチン Pending JP2024156682A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261647615P 2012-05-16 2012-05-16
US61/647,615 2012-05-16
JP2020065482A JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022104015A Division JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン

Publications (2)

Publication Number Publication Date
JP2024156682A JP2024156682A (ja) 2024-11-06
JP2024156682A5 true JP2024156682A5 (enExample) 2024-12-23

Family

ID=49584234

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015512776A Withdrawn JP2015518835A (ja) 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン
JP2018008606A Pending JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン
JP2020065482A Pending JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A Pending JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン
JP2024110688A Pending JP2024156682A (ja) 2012-05-16 2024-07-10 癌幹細胞を標的とした癌ワクチン

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2015512776A Withdrawn JP2015518835A (ja) 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン
JP2018008606A Pending JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン
JP2020065482A Pending JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A Pending JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン

Country Status (16)

Country Link
US (3) US10485858B2 (enExample)
EP (4) EP2849772A4 (enExample)
JP (5) JP2015518835A (enExample)
CA (2) CA3183703A1 (enExample)
CY (1) CY1124512T1 (enExample)
DK (1) DK3536334T3 (enExample)
ES (2) ES2890529T3 (enExample)
HR (1) HRP20211432T1 (enExample)
HU (1) HUE056350T2 (enExample)
LT (1) LT3536334T (enExample)
PL (1) PL3536334T3 (enExample)
PT (1) PT3536334T (enExample)
RS (1) RS62406B1 (enExample)
SI (1) SI3536334T1 (enExample)
SM (1) SMT202100545T1 (enExample)
WO (1) WO2013173411A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2849772A4 (en) 2012-05-16 2016-03-02 Stemline Therapeutics Inc TUMOR VACCINES TREATED AGAINST CANCER STEM CELLS
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
CN117801066A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
WO2019197563A2 (en) * 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
FI3773689T3 (fi) * 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
WO2021155501A1 (zh) * 2020-02-05 2021-08-12 瓦克斯恩有限公司 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AU677772B2 (en) 1991-10-07 1997-05-08 Biogen Idec Ma Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA -3 interaction
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
FI972514A7 (fi) 1994-12-14 1997-08-12 Scripps Research Inst Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
MXPA03007878A (es) 2001-03-02 2004-07-08 Medimmune Inc Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 il­9 항체 및 그의 용도
JP2004353820A (ja) 2003-05-30 2004-12-16 Toyota Motor Corp トリポート型等速ジョイント部品およびトリポート型等速ジョイント
EP1651671A2 (en) 2003-07-30 2006-05-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Epha2 t-cell epitope agonists and uses therefor
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
ES2323588T3 (es) 2003-11-19 2009-07-21 Merck Patent Gmbh Proteinas que pertenecen a la familia bcl-2 y fragmentos de las mismas, y su uso en pacientes con cancer.
US20050153923A1 (en) 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
CA2600898C (en) 2004-12-07 2016-08-23 Toray Industries, Inc. Novel cancer antigen peptide and the use thereof
CA2593714C (en) 2005-02-04 2013-09-10 Survac Aps Survivin peptide vaccine
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
WO2007053648A2 (en) 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2008030538A2 (en) 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
CA2698597A1 (en) 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Monitoring cancer stem cells
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
AU2008207945A1 (en) 2007-01-22 2008-07-31 Macrogenics West, Inc. Human cancer stem cells
JP5438676B2 (ja) 2007-07-19 2014-03-12 ヘルス リサーチ インコーポレイテッド 癌ワクチンとしてのサバイビンペプチド
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2011293522B2 (en) 2010-08-24 2015-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US8801711B2 (en) * 2011-06-16 2014-08-12 Clifford T. Solomon Skull clamp system with pressure limiting and alarm systems
EP2849772A4 (en) 2012-05-16 2016-03-02 Stemline Therapeutics Inc TUMOR VACCINES TREATED AGAINST CANCER STEM CELLS

Similar Documents

Publication Publication Date Title
JP2024156682A5 (enExample)
AU2018203170B2 (en) Multimeric Fusion Protein Vaccine And Immunotherapeutic
Park et al. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells
JP2018509935A5 (enExample)
JP2020147591A5 (enExample)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
Cui et al. A novel tetrameric gp3501–470 as a potential Epstein–Barr virus vaccine
JP2013534532A5 (enExample)
JP2018510215A5 (enExample)
JP2018127458A5 (enExample)
RU2019105550A (ru) Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования
AU2021221287B2 (en) Engineered anti-IL-2 antibodies
JP2016529229A5 (enExample)
IE66267B1 (en) Immunogenic compositions against gastrin peptides
Shukla et al. Presentation of HER2 epitopes using a filamentous plant virus-based vaccination platform
RU2015154795A (ru) Иммуногенная композиция, ее включающая вакцина, набор для приготовления вышеуказанной композиции и способ лечения заболеваний, связанных с патологией секреции гастрина
JP2019526244A5 (enExample)
US20190358313A1 (en) New flavivirus vaccine
CN1316431A (zh) 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
CA2967778A1 (en) Anti-thyroglobulin t cell receptors
JP2021506817A5 (enExample)
US20180078636A1 (en) Hepatitis b therapeutic vaccines
US8563003B2 (en) Method for the treatment of malignant and infectious chronic diseases
ES2908071T3 (es) Composición de vacuna y usos de la misma
US8575319B2 (en) Cleavable vaccine compositions and uses thereof and methods of making and using the same